- Home
- ATOS vs SGMO Comparison
ATOS vs SGMO Comparison
Compare ATOS & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- SGMO
- Stock Information
- Founded
- ATOS 2009
- SGMO 1995
- Country
- ATOS United States
- SGMO United States
- Employees
- ATOS N/A
- SGMO N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATOS Health Care
- SGMO Health Care
- Exchange
- ATOS Nasdaq
- SGMO Nasdaq
- Market Cap
- ATOS 120.4M
- SGMO 122.8M
- IPO Year
- ATOS 2012
- SGMO 2000
- Fundamental
- Price
- ATOS $0.86
- SGMO $0.58
- Analyst Decision
- ATOS Strong Buy
- SGMO Strong Buy
- Analyst Count
- ATOS 3
- SGMO 7
- Target Price
- ATOS $6.25
- SGMO $5.29
- AVG Volume (30 Days)
- ATOS 1.3M
- SGMO 4.5M
- Earning Date
- ATOS 11-12-2025
- SGMO 11-06-2025
- Dividend Yield
- ATOS N/A
- SGMO N/A
- EPS Growth
- ATOS N/A
- SGMO N/A
- EPS
- ATOS N/A
- SGMO N/A
- Revenue
- ATOS N/A
- SGMO $81,706,000.00
- Revenue This Year
- ATOS N/A
- SGMO $28.47
- Revenue Next Year
- ATOS N/A
- SGMO N/A
- P/E Ratio
- ATOS N/A
- SGMO N/A
- Revenue Growth
- ATOS N/A
- SGMO 565.52
- 52 Week Low
- ATOS $0.55
- SGMO $0.41
- 52 Week High
- ATOS $1.66
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- ATOS 39.96
- SGMO 41.32
- Support Level
- ATOS $0.86
- SGMO $0.56
- Resistance Level
- ATOS $0.91
- SGMO $0.62
- Average True Range (ATR)
- ATOS 0.05
- SGMO 0.04
- MACD
- ATOS -0.02
- SGMO -0.01
- Stochastic Oscillator
- ATOS 4.01
- SGMO 10.38
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.